Abstract
The aim of the present study was to prepare and characterize novel vesicular carrier elastic liposomes, of most commonly used non-steroidal anti-inflammatory agent diclofenac for its sustained and targeted delivery. Elastic liposomes of diclofenac were prepared and characterized in vitro and in vivo. The effect of different formulation variables like type of surfactant, concentration of surfactant and dose of drug on transdermal flux, amount of drug deposited into the skin, muscle and plasma concentration was investigated. The biological activity of optimized formulation was evaluated using carrageenan induced rat paw edema model and results were compared with commercial hydrogel formulation. The elastic liposomal formulations achieved muscle drug concentration between 2.2 ± 0.14 to 5.3 ± 0.22 μg/g at 12hr. The same dose of commercial hydrogel formulation produced drug levels between 0.41 ± 0.07 to 1.1 ± 0.09 μg/g in the muscle. Plasma concentration study showed regiospecificity of elastic liposomal formulation. The results of in vivo study revealed that incorporation of diclofenac in elastic liposomes increased its biological activity two fold as compared to commercial hydrogel formulation. The results of the present study demonstrated greater effectiveness of dermaly applied diclofenac elastic liposomal formulation in comparison to conventional delivery system. The optimized elastic liposomal formulation offers a promising means for the non-invasive treatment of local pain and inflammation by topical application.
Keywords: skin, percutaneous absorption, elastic liposomes, sustained, targeted, transdermal delivery, Biological activity, regiospecificity
Current Drug Delivery
Title: Transdermal Delivery of An Analgesic Agent Using Elastic Liposomes: Preparation, Characterization and Performance Evaluation
Volume: 2 Issue: 3
Author(s): Subheet Jain, N. Jain, D. Bhadra, A. K. Tiwary and N. K. Jain
Affiliation:
Keywords: skin, percutaneous absorption, elastic liposomes, sustained, targeted, transdermal delivery, Biological activity, regiospecificity
Abstract: The aim of the present study was to prepare and characterize novel vesicular carrier elastic liposomes, of most commonly used non-steroidal anti-inflammatory agent diclofenac for its sustained and targeted delivery. Elastic liposomes of diclofenac were prepared and characterized in vitro and in vivo. The effect of different formulation variables like type of surfactant, concentration of surfactant and dose of drug on transdermal flux, amount of drug deposited into the skin, muscle and plasma concentration was investigated. The biological activity of optimized formulation was evaluated using carrageenan induced rat paw edema model and results were compared with commercial hydrogel formulation. The elastic liposomal formulations achieved muscle drug concentration between 2.2 ± 0.14 to 5.3 ± 0.22 μg/g at 12hr. The same dose of commercial hydrogel formulation produced drug levels between 0.41 ± 0.07 to 1.1 ± 0.09 μg/g in the muscle. Plasma concentration study showed regiospecificity of elastic liposomal formulation. The results of in vivo study revealed that incorporation of diclofenac in elastic liposomes increased its biological activity two fold as compared to commercial hydrogel formulation. The results of the present study demonstrated greater effectiveness of dermaly applied diclofenac elastic liposomal formulation in comparison to conventional delivery system. The optimized elastic liposomal formulation offers a promising means for the non-invasive treatment of local pain and inflammation by topical application.
Export Options
About this article
Cite this article as:
Jain Subheet, Jain N., Bhadra D., Tiwary K. A. and Jain K. N., Transdermal Delivery of An Analgesic Agent Using Elastic Liposomes: Preparation, Characterization and Performance Evaluation, Current Drug Delivery 2005; 2 (3) . https://dx.doi.org/10.2174/1567201054368020
DOI https://dx.doi.org/10.2174/1567201054368020 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting IAPs as An Approach to Anti-Cancer Therapy
Current Topics in Medicinal Chemistry Protein Oxidation and Proteolytic Signalling in Aging
Current Pharmaceutical Design Multiplex Analysis of Cardiac Hypertrophic Signaling: Reduced in vivo Phosphorylation of Glycogen Synthase Kinase-3β and Proline-Rich Akt Substrate (PRAS40)
Current Signal Transduction Therapy Editorial [Hot topic: Developing New Anti-Cancer Drugs (Guest Editor: Ricardo De Souza Pereira)]
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Potential of Targeting Glypican-3 in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Prevention of Endothelial Dysfunction and Cardiovascular Disease by n-3 Fatty Acids-Inhibiting Action on Oxidative Stress and Inflammation
Current Pharmaceutical Design An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
Anti-Cancer Agents in Medicinal Chemistry The Role of Monocytes and Macrophages in the Pathogenesis of HIV-1 Infection
Current Medicinal Chemistry Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
Current Drug Targets Tumor Systems Need to be Rendered Usable for a New Action-Theoretical Abstraction: The Starting Point for Novel Therapeutic Options
Current Cancer Therapy Reviews PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Hypersensitivity Reactions to Anticoagulant Drugs
Current Pharmaceutical Design Apoptosis in Obstructive Nephropathy
Current Pediatric Reviews Interaction of Autophagy and Toll-Like Receptors: A Regulatory Cross- Talk - Even in Cancer Cells?
Current Drug Targets Targeting HIV: Past, Present and Future
Infectious Disorders - Drug Targets CRP and Anti-CRP Autoantibodies in Systemic Lupus Erythematosus
Current Rheumatology Reviews Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design The Molecular Concept of Atheromatous Plaques
Current Drug Targets